Dose Insider / Analyses / Zepbound weight loss chart
Zepbound Weight Loss Chart: Week by Week, From the Trials
Updated November 19, 2026 · 24 min read · FDA label, SURMOUNT-1, trial registry
On the top dose of Zepbound, the average person in the main trial was down 3% of body weight at week 4, 9% at week 12, 15% at week 24, 20% at week 48 and 22% at week 72. For someone starting at 231 lb, the trial average, that is 7, 20, 34, 47 and 51 lb.
Those figures come from one drawing: Figure 3 of the Zepbound prescribing information, which plots the average weight of 2,539 people in the SURMOUNT-1 trial at every visit for 72 weeks.1 Most charts passed around online are rough guesses, and they disagree with one another. This one is the trial's own curve, read off the label point by point.
The calculator below turns the curve into your own pounds for any week on 5, 10 or 15 mg. The rest of the page covers what an average cannot tell you: your odds of a given result, what a slow start means and when the loss levels off. It also explains why the same drug gets quoted at 15%, 16%, 21% and 22.5%.
How much weight should I have lost by now?
Enter the weight you started at, pick the dose you are heading for, and move the slider to your week. Add your weight today and the chart shows where you stand against the trial average. Add a goal weight and it finds the week in which the average got there.
Trial averages for people who stayed in the study, not a forecast for one person. Between visits the line is drawn straight. The Wegovy line comes from a separate trial.
Log every weigh-in and every dose, and watch your own curve grow week by week.
Track it in Dose InsiderAll three dose groups took the same doses for the first 8 weeks, 2.5 mg and then 5 mg, so their lines start as one. The 5 mg group stayed there. The other two kept climbing by 2.5 mg every 4 weeks, reaching 10 mg in week 13 and 15 mg in week 21.1,2
| Week | 5 mg | 10 mg | 15 mg | Placebo | 15 mg, from 231 lb |
|---|---|---|---|---|---|
| 4 | 3.2% | 3.2% | 3.2% | 1.1% | 7 lb |
| 8 | 6.0% | 6.0% | 6.0% | 1.7% | 14 lb |
| 12 | 7.9% | 8.6% | 8.6% | 2.1% | 20 lb |
| 16 | 9.2% | 10.9% | 10.9% | 2.4% | 25 lb |
| 20 | 10.4% | 12.6% | 12.6% | 2.5% | 29 lb |
| 24 | 11.6% | 14.3% | 14.6% | 2.9% | 34 lb |
| 36 | 13.7% | 17.4% | 18.1% | 3.3% | 42 lb |
| 48 | 15.0% | 19.1% | 20.2% | 3.1% | 47 lb |
| 60 | 16.0% | 20.6% | 21.6% | 3.3% | 50 lb |
| 72 | 16.1% | 20.9% | 22.0% | 3.3% | 51 lb |
The trial enrolled adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and without diabetes. Their average age was 45, with a range of 18 to 84, and their average weight 104.8 kg, or 231 lb; 68% were women. By race, 71% were White, 11% Asian, 9% American Indian or Alaska Native and 8% Black, and 48% were Hispanic or Latino.1,3 Only about 1 participant in 20 had a BMI under 30, so the chart says least about people at the lighter end.2 Everyone, the placebo group included, was told to eat about 500 kcal a day less than they needed and to exercise at least 150 minutes a week.1 That is why the placebo line drops by about 3% too, and it means the chart shows the drug together with a diet, not in place of one.
The same curve in pounds, for three starting weights on the way to 15 mg:
| Week | From 200 lb | From 250 lb | From 300 lb |
|---|---|---|---|
| 4 | 6 lb | 8 lb | 10 lb |
| 12 | 17 lb | 22 lb | 26 lb |
| 24 | 29 lb | 37 lb | 44 lb |
| 48 | 40 lb | 51 lb | 61 lb |
| 72 | 44 lb | 55 lb | 66 lb |
What does each stage of the chart look like?
Weeks 1 to 4: the starter dose
Everyone takes 2.5 mg. The average loss is 3.2%, about 7 lb from 231 lb. The drug reaches a steady level in the blood only after 4 weekly doses, so the first shots act on a level that is still building.1
Weeks 5 to 12: 5 mg, then 7.5 mg
The dose doubles to 5 mg in week 5, and by week 8 the average loss is 6.0%. People whose plan is 5 mg stop climbing here. The others move to 7.5 mg in week 9. At week 12 the averages are 7.9% and 8.6%, and 82% of people have lost at least 5%. Nausea, vomiting and diarrhea mostly come in these weeks of rising doses and ease afterwards.1
Weeks 13 to 24: the climb to full dose
The dose reaches 10 mg in week 13 and 15 mg in week 21. In pounds this is the biggest stretch of the trial: the 15 mg group went from 8.6% to 14.6%, another 14 lb for a 231 lb person. By week 24 the three groups stand at 11.6%, 14.3% and 14.6%. People who started in the overweight range begin to level off about now.
Weeks 25 to 48: slower, still falling
The weekly pace drops to about a third of what it was in the first month, and the loss keeps adding up: from 14.6% to 20.2% on 15 mg, and from 11.6% to 15.0% on 5 mg. For people who started with a BMI above 35, the middle of this stretch is where the typical plateau begins.
Weeks 49 to 72: levelling off
The 15 mg line moves from 20.2% to 22.0%, about 4 lb in 24 weeks for a 231 lb person, and the 5 mg line from 15.0% to 16.1%. By week 72 nine people in ten had reached a plateau.6
How much do people lose in the first month?
About 3% of their starting weight, or 7 lb for a 231 lb person. The placebo group lost 1.1% over the same 4 weeks, so roughly two-thirds of the first month's loss is the drug.1
This happens on 2.5 mg, the smallest dose. The label describes 2.5 mg as a dose for starting treatment and does not approve it for long-term use.1 Its job is to let the stomach adjust before the dose goes up. The first month is still the fastest of the whole 72 weeks, at 0.8% of body weight a week.
By the end of month two, on 5 mg, the average loss was 6.0%, and by week 12 it was 7.9% for people held at 5 mg and 8.6% for those who had moved to 7.5 mg.
How many pounds a week is normal?
It depends on which week you ask about. The weekly pace is highest at the start and falls in steps. For a 231 lb person on the way to 15 mg it is about 1.8 lb a week in the first month and 1.2 lb a week between weeks 13 and 24. After week 36 it is under half a pound a week.
Uses the starting weight from the calculator above. Each bar is the change between two trial visits divided by the weeks between them.
Averaged over all 72 weeks, the 15 mg group lost 0.3% of starting weight a week, or 0.7 lb. That average is a poor guide to any single week. A person who expects 2 lb every week because the first month went that way will read month eight as a failure, when the trial average by then was a third of that.
When will I reach my goal weight?
Type a goal weight into the calculator and it finds the week in which the trial average got there. On 15 mg the average passed 10% in week 15, 15% in week 26 and 20% in week 47. On 10 mg the same marks came in weeks 15, 27 and 56. On 5 mg the average reached 10% in week 19 and 15% in week 48, and it never reached 20%.
For a 231 lb person, 30 lb is 13% of body weight. The 15 mg average got there in week 21 and the 5 mg average in week 32. Fifty pounds is 21.6%, which the 15 mg average reached in week 62 and the lower doses did not reach.
An average that stops short of a goal does not rule the goal out. The 5 mg average ended at 16.1%, yet three in ten people on 5 mg lost a fifth of their weight or more.1 The odds further down show how many people beat the average, and by how much.
Does a higher dose take off more?
Yes, with most of the gain between 5 mg and 10 mg. At week 72 the people still in the study were down 16.1% on 5 mg, 20.9% on 10 mg and 22.0% on 15 mg.1 Going from 5 to 10 mg added 4.8 points. Going from 10 to 15 mg added 1.1.
The lines separate only after the doses do. Until week 8 the three groups were on identical doses and lost identical amounts. The 5 mg line peels away at week 12, and the 10 and 15 mg lines stay together until week 24.
A person who stays at 5 mg is following the 5 mg line: the same first 8 weeks and a result about 6 points lower at week 72. Staying at 10 mg costs about 1 point against 15 mg. Many people do stay lower. After 6 months outside trials, 58% of tirzepatide users had not reached 10 mg.10
Money is one reason, since Lilly's self-pay price is $399 a month for 5 mg and $449 for 7.5 mg and up. Over 72 weeks that comes to $7,082 on a 5 mg plan and $7,882 on a 15 mg plan. Divided by the trial-average loss from 231 lb, it is about $190 for each pound on 5 mg and $155 on 15 mg. The lower dose is cheaper by the month and dearer by the pound. The prices and the arithmetic are in our head-to-head cost section.
The label accepts 5, 10 or 15 mg as a long-term dose and says to weigh the response against how well the dose is tolerated.1 Waist size and blood pressure followed weight. The waist shrank by 14.0, 17.7 and 18.5 cm on the three doses, against 4.0 cm on placebo, and systolic blood pressure fell by 6.6 to 7.7 mmHg, against 1.0.1
What are my odds of losing 10, 15 or 20%?
An average hides the spread. On 15 mg, 57 people in 100 lost a fifth of their body weight or more, and 9 in 100 lost less than 5%. Pick a dose and a goal.
“Everyone who started” is the FDA label's count, with missing weights filled in. “While taking the drug” is the trial registry's count, which leaves out weights measured after a person stopped treatment.
Set a goal weight and see how far each weigh-in moves you toward it.
Track it in Dose Insider| Everyone who started | While taking the drug | |||||
|---|---|---|---|---|---|---|
| Lost at least | 5 mg | 10 mg | 15 mg | 5 mg | 10 mg | 15 mg |
| 5% | 85.1% | 88.9% | 90.9% | 89.4% | 96.2% | 96.3% |
| 10% | 68.5% | 78.1% | 83.5% | 73.4% | 85.9% | 90.1% |
| 15% | 48.0% | 66.6% | 70.6% | 50.2% | 73.6% | 78.2% |
| 20% | 30.0% | 50.1% | 56.7% | 31.6% | 55.5% | 62.9% |
On placebo, with the same diet and exercise advice, 34.5% lost at least 5% and 3.1% lost at least 20%.1,3
I am behind the chart. Is it not working?
Probably it is working, more slowly. This is the most common worry about these drugs. In a year of posts from eight GLP-1 forums on Reddit we counted 2,667 threads about how much and how fast the weight should come off, and three in four were questions. One of the most-commented asked whether a doctor had lied about what to expect.
Two analyses of SURMOUNT-1 followed the slow starters to the end. The first drew the line at week 8. By then 62% of people on Zepbound had lost at least 5% of their weight, and 38% had not.5 The second drew it at week 12, when 82% had passed 5% and 18% had not.4
The 18% are the group to watch, and their story is better than the forums suggest. Of those who had lost less than 5% by week 12, 70% reached 5% by week 24 and 90% reached it by week 72. By the end 59% of them had lost at least 10%, 30% at least 15% and 17% at least 20%. Their average loss was 11.0%, or 12 kg.4
They did finish well behind the early group, which averaged 22.5%. And dose still mattered for them. People under 5% at week 8 ended at 10.6% on 5 mg, 14.8% on 10 mg and 18.1% on 15 mg.5
Who were the slow starters? More often men (45% of the late group against 30% of the early group), and heavier at the start, 110.2 kg against 103.6 kg.4 A heavier person loses the same pounds as a smaller share of body weight, so the percentage moves more slowly.
And if I am ahead of the chart?
Losing faster than the average is common, and the trial data do not treat it as a warning sign in itself. In the head-to-head trial against Wegovy, 44% of people on Zepbound had lost 15% or more by week 24. They reported more stomach, gut and gallbladder problems than slower responders and were just as likely to stay on treatment.17
A slow start is different from side effects that will not settle. The label lists severe stomach problems, dehydration that can harm the kidneys, gallbladder disease and pancreatitis among its warnings, and those are reasons to call the prescriber whatever the scale says.1
How much of the chart is the diet and exercise?
About 3 points of the 22. The placebo group got the same instructions, a 500 kcal daily deficit and 150 minutes of exercise a week, and its line bottoms out at 3.3%. One person in three on placebo lost at least 5%, and 3 in 100 lost 20%.1
That does not make the diet optional. Every number on this page comes from people who were given both the drug and the advice, and the label approves Zepbound for use together with a reduced-calorie diet and more physical activity. What the placebo line does show is how little the same advice achieved alone over 72 weeks. In the trial that started with 12 weeks of intensive coaching, the people then moved to placebo regained 2.5% in spite of continued advice.1
Do I need side effects for it to work?
No. In SURMOUNT-1, people on Zepbound who never reported nausea had lost 19.7% of their weight by week 72. People who reported nausea had lost 22.0%, and people with any nausea, vomiting or diarrhea 22.5%. The analysis estimated that these symptoms explained at most 3.1% of the total weight loss.14 The label puts the effect down to appetite: people on the drug take in fewer calories.1
The side effects are common all the same. Across the two main trials, nausea was reported by 25% to 29% of people on Zepbound against 8% on placebo. For diarrhea the figures were 19% to 23% against 8%, for constipation 11% to 17% against 5%, and for vomiting 8% to 13% against 2%.1 Higher doses brought more vomiting and diarrhea and no more nausea. Gallstones were reported by 1.1% of people on Zepbound and 1% on placebo.
When does the weight loss stop?
For most people in the trial, between week 24 and week 36. Researchers defined a plateau as the first 12-week stretch in which weight changed by less than 5%, with every later stretch staying under 5% as well. By that definition 88% to 90% of participants had reached a plateau by week 72.6
The timing depended on starting size. People who began in the overweight range, with a BMI of 27 to 30, reached a plateau after a median of 24.3 weeks. With a BMI of 30 to 35 it took 26.0 weeks, and above 35 it took 36.1 weeks. All of them lost at the same rate for the first 24 weeks, 13% to 15%. After that, people with a BMI above 40 lost another 9.7% and people in the overweight range another 4.6%.6
Other things pushed the plateau later. It came 4.4 weeks later on 10 mg and 6.7 weeks later on 15 mg than on 5 mg, and 4.2 weeks later in women than in men.6 A later plateau went with a larger total loss.
On the chart the same thing shows as a flattening line. Between week 60 and week 72 the 15 mg group lost another 0.4% of body weight, less than 1 lb for a 231 lb person over three months. A scale that has not moved for 3 weeks in month three is a pause. A scale that has not moved for 12 weeks after month eight is what the trial looked like for nearly everyone.
Why do before-and-after posts beat the chart?
On the forums the celebrated results run to 100 lb and more. In our count of a year of Reddit posts, progress and before-and-after threads were the largest category, 11,048 of them, three and a half times the number of threads about stalls. Several of the most upvoted reported losses of 100 to 210 lb.
Three things explain the distance from a chart that ends at 51 lb. The first is starting weight. The trial average is 22% of 231 lb; the same 22% of 400 lb is 88 lb. The second is the spread around the average. Of 1,545 trial participants who stayed on treatment, about 35% lost a quarter of their weight or more, and theirs are the results that get posted.4 The third is time. In SURMOUNT-4, people who had done well for 36 weeks and kept going reached 25.3% at 88 weeks.9
None of this makes the posts false. They come from the top of the range, which an average line cannot show.
Why do some people lose more than others?
Sex
Women lose more. At Mayo Clinic, among 1,039 patients who took tirzepatide without a break for at least a year, women had lost 15.1% of their weight at 15 months and men 10.7%. Age made no difference once sex was accounted for.8 The head-to-head trial against Wegovy found the same gap, about 6 percentage points, on both drugs.13
Type 2 diabetes
People with type 2 diabetes lose less on the same dose. In the trial that enrolled them, the average loss at 72 weeks was 12.8% on 10 mg and 14.7% on 15 mg, against 19.5% and 20.9% in people without diabetes.1 The gap opens early and keeps widening. Switch the calculator to “With type 2 diabetes” to see that curve, read from Figure 4 of the label.
| With type 2 diabetes | Without diabetes | |||
|---|---|---|---|---|
| Week | 10 mg | 15 mg | 10 mg | 15 mg |
| 4 | 2.3% | 2.3% | 3.2% | 3.2% |
| 12 | 6.4% | 6.4% | 8.6% | 8.6% |
| 24 | 10.1% | 11.3% | 14.3% | 14.6% |
| 48 | 12.4% | 14.5% | 19.1% | 20.2% |
| 72 | 13.0% | 15.3% | 20.9% | 22.0% |
Weight already lost by diet
A third trial put 806 people through 12 weeks of intensive diet and exercise coaching and kept only the 579 who lost at least 5%. Their average weight had gone from 109.5 kg to about 102 kg. Half then got Zepbound at 10 or 15 mg and half placebo. Over the next 72 weeks the Zepbound group lost a further 18.4% and the placebo group regained 2.5%.1 Weight lost before the first shot did not come out of the drug's share.
Starting size
People who start heavier lose a larger share of their weight and far more pounds. Across the three doses, people who began in the overweight range had lost about 18% by week 72, people with a BMI of 30 to 35 about 21.5%, and people with a BMI above 35 about 23%.6 In pounds the gap is wider: 18% of 180 lb is 32 lb, and 23% of 290 lb is 67 lb.
The first weeks
Early loss predicts later loss on average. People past 5% at week 8 finished at 23.3%, the rest at 14.6%.5 It predicts poorly for one person, as the slow starters who reached 20% show.
Staying on the drug
The chart assumes a shot every week for 72 weeks. Of the people assigned to Zepbound, about 10% had no weight recorded at week 72.1 Outside trials far more people stop, which is the main reason real-world results fall short of the curve.
Do people outside trials match the chart?
They run behind it, mostly because they take lower doses and stop sooner. In US health records for 1,003 adults without diabetes who started tirzepatide between December 2023 and June 2024 and kept filling it, the average loss after 6 months was 11.2%.10 The trial's 10 and 15 mg groups were at 14.3% and 14.6% by week 24. Only 42% of the real-world group had reached 10 mg by then, while the trial schedule put everyone assigned to that dose on it by week 13.
An earlier study of 9,193 matched tirzepatide users found that 56% had stopped the drug by the end of follow-up.11 And the Mayo Clinic patients who did stay on for 15 months, the women at 15.1% and the men at 10.7%, were still below the trial's 20% at week 48.8 In Cleveland Clinic records for 20,486 adults on semaglutide or tirzepatide, people who stayed on their first drug were down 10.9% after two years.15
So the label curve is closer to a best case than a typical case: full dose on schedule, no missed months, regular check-ins. A person on 5 mg should read the 5 mg line, and a person who paused for two months should not expect to be where the slider says. What a late or missed shot does to the drug level is covered in why the day before your shot feels different.
Is the weight lost fat or muscle?
About three-quarters fat. A sub-study scanned 160 SURMOUNT-1 participants with DXA, an X-ray method that separates fat from lean tissue, at the start and at week 72. On Zepbound body weight fell by 21.3%, fat mass by 33.9% and lean mass by 10.9%.7
Of the weight lost, roughly 75% was fat and 25% lean tissue. The split was the same in the placebo group, which lost far less, and the authors note that weight loss by dieting usually divides in the same way.7 For a person who loses 50 lb, that is about 37 lb of fat and 13 lb of lean tissue, which includes muscle, water and organ mass.
What happens after 72 weeks?
The weight holds for as long as the drug continues. SURMOUNT-1 kept its participants with prediabetes on treatment for 176 weeks, more than three years. Their loss at that point was 15.4% on 5 mg, 19.9% on 10 mg and 22.9% on 15 mg while on the drug, close to the week-72 figures. Over those three years 1.2% of the 762 people on Zepbound developed type 2 diabetes, against 12.6% of the 270 on placebo.3
A different trial, SURMOUNT-4, shows both directions. It gave 783 people Zepbound for 36 weeks and then randomly assigned the 670 who were still on it to keep taking the drug or to switch to placebo. Average weight had gone from 107.3 kg to about 85 kg by week 36, a loss of 20.9%. Over the next year the people who continued lost another 5.5%, for a total of 25.3%. The people moved to placebo regained 14.0%.1,9
The 25.3% is higher than anything on the SURMOUNT-1 chart because SURMOUNT-4 counted only people who had already tolerated 10 or 15 mg for 36 weeks. We go through the regain data in why people stop GLP-1s.
Can the loss be held on a lower dose?
Most of it, on average. SURMOUNT-MAINTAIN, published in The Lancet in June 2026, is the first trial to test the idea. In it 441 adults took Zepbound at the highest dose they could tolerate for 60 weeks. Then 378 of them were randomly assigned to stay on that dose, to step down to 5 mg, or to switch to placebo for another year.16
At week 112 the people who stayed on the full dose were down 21.9% from their starting weight, the people moved to 5 mg were down 16.6%, and the people moved to placebo 9.9%. A regain of at least half the lost weight happened to 8% on the full dose, 25% on 5 mg and 67% on placebo.
Stepping down to 5 mg kept about three-quarters of the loss on average and protected three people in four from a large regain. Stopping protected one in three. The trial cannot yet say which people do well on the lower dose, and its authors call for follow-up longer than a year.
How does the Wegovy chart compare?
Switch the comparison line in the calculator to Wegovy 2.4 mg. That curve comes from Figure 6 of the Wegovy label, the STEP 1 trial, read the same way.12 The two drugs track each other for about 8 weeks, Zepbound at 6.0% and Wegovy at 4.0%, and then the gap widens: 14.6% against 10.6% at week 24, and about 22% against 16% at the end.
Those are two trials with different participants, so the distance between the lines is only a rough guide. The one trial that randomized people to one drug or the other found 20.2% against 13.7% at 72 weeks.13 The details are in Wegovy vs Zepbound: what the head-to-head actually showed.
Why do sources give 15%, 16%, 21% and 22.5% for one drug?
Because the same trial was analyzed three ways, and each one answers a slightly different question.
| Week 72 | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Everyone who started, missing weights filled in | 15.0% | 19.5% | 20.9% | 3.1% |
| People weighed at week 72 | 16.1% | 20.9% | 22.0% | 3.3% |
| While taking the drug | 16.0% | 21.4% | 22.5% | 2.4% |
The first row is the FDA label's headline and the most cautious. It counts all 2,539 people who were randomized. About 10% of each Zepbound group had no week-72 weight, and the statisticians filled those in, mostly from people who had stopped the drug but still came back to be weighed.1
The second row is the curve on this page: the plain average of everyone who showed up at each visit. It runs about a point better than the first row because people who leave a trial early tend to be the ones losing less.
The third row is what the drug does while a person keeps taking it, and it is where the often-quoted 22.5% comes from.2,3 None of the three is wrong. Someone deciding whether to start should look at the first, and someone tracking a steady course of treatment at the second or third.
How much weight can you lose on Zepbound in 3 months, and in 6?
At week 12 the trial average was 7.9% on a 5 mg plan and 8.6% on the way to higher doses, 18 to 20 lb from 231 lb. At week 24 it was 11.6% on 5 mg, 14.3% on 10 mg and 14.6% on 15 mg, or 27 to 34 lb.1
Why am I not losing weight on 2.5 mg?
The 2.5 mg dose is a starter that the label does not approve for long-term use, and the trial's first month averaged 3.2%. Four in ten people were still under 5% after 8 weeks, on 5 mg by then, and most of them went on to lose 10% or more.1,5
How much will I lose on 7.5 mg or 12.5 mg?
The trial did not test them as long-term doses. They were 4-week steps on the way to 10 and 15 mg, and the label lists 5, 10 and 15 mg for maintenance.1 A result between the neighbouring lines is a fair guess, and no trial has measured it.
Does Zepbound stop working after a while?
The loss levels off, and that is different from the drug stopping. People kept on treatment for 176 weeks held the weight they had lost by week 72, and people taken off it regained.3,9
How long does Zepbound take to start working?
The first trial visit was at week 4, and the average loss by then was already 3.2% against 1.1% on placebo.1 The label curve has no earlier point, so the trial cannot say what the first week or two look like.
Is this chart the same for Mounjaro?
Mounjaro is the same drug, tirzepatide, sold for type 2 diabetes. The curve here comes from people without diabetes. In the trial of people with diabetes, the loss at 72 weeks was 12.8% on 10 mg and 14.7% on 15 mg.1
What is the average weight loss on Zepbound 5 mg?
15.0% at 72 weeks counting everyone who started, and 16.1% among people still in the study, which is 35 to 37 lb from 231 lb. Three in ten people on 5 mg lost at least 20%.1
How the chart was built
The FDA label prints the week-by-week curve as a drawing without a table of values. We rendered the page at three times its size and located the centre of every marker by pixel. Two checks came out within 0.1 percentage point: the week-72 values printed beside the curve and the separate column of adjusted week-72 values. The 20-week result posted in the trial registry, 13.2 kg for the two higher doses, matches the curve as well.1,3
Where markers overlap, we used one value: at weeks 4 and 8 for all three doses, which were identical doses at that point, and at weeks 12 to 20 for the 10 and 15 mg groups. Values are accurate to about 0.2 points. The curve for people with type 2 diabetes was read from Figure 4 of the same label, and the Wegovy line from its own label, in the same way.
The calculator multiplies your starting weight by the curve and draws straight lines between visits. The weekly pace is the change between two visits divided by the weeks between them. The odds are the published shares for the four thresholds the trial reported. The Reddit count covers post titles from November 19, 2025 to November 19, 2026 in r/Zepbound, r/Mounjaro, r/Semaglutide, r/Ozempic, r/WegovyWeightLoss, r/GLP1_Ozempic_Wegovy, r/tirzepatidecompound and r/CompoundedSemaglutide, 132,145 posts in all. None of this predicts an individual result, and none of it is medical advice.
Sources
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-042. U.S. Food and Drug Administration, 2026; sections 2, 5, 6, 12 and 14, Tables 1 to 6, Figures 3 and 4. accessdata.fda.gov
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
- ClinicalTrials.gov. SURMOUNT-1, NCT04184622, study results. clinicaltrials.gov
- Ard J, Lee CJ, Gudzune K, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab 2025;27:5064-5071. doi:10.1111/dom.16554
- Kokkinos A, Thethi T, Lee CJ, et al. Tirzepatide efficacy and tolerability according to early weight response: a post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials. Diabetes Obes Metab 2026;28:8367-8377. doi:10.1111/dom.71009
- Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15:e12734. doi:10.1111/cob.12734
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720-2729. doi:10.1111/dom.16275
- Castaneda R, Bechenati D, Rivera Gutierrez RJ, et al. Sex, not age, predicts weight loss outcomes with tirzepatide: a retrospective analysis. Obesity (Silver Spring) 2026;34 Suppl 2:132-145. doi:10.1002/oby.70231
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
- le Roux CW, Done N, Brnabic AJM, et al. Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. J Endocrinol Invest 2026;49:413-423. doi:10.1007/s40618-025-02792-1
- Rodriguez PJ, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med 2024;184:1056-1064. doi:10.1001/jamainternmed.2024.2525
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-033. U.S. Food and Drug Administration, 2026; Figure 6. accessdata.fda.gov
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
- Rubino DM, Pedersen SD, Connery L, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab 2025;27:1826-1835. doi:10.1111/dom.16176
- Healio. Continued obesity treatment linked to long-term weight loss. Report on Gasoyan H, et al., ObesityWeek, November 14, 2026. healio.com
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
- Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med 2026;139:913-921. doi:10.1016/j.amjmed.2026.03.010
Keep your own chart, one weigh-in at a time.
Open Dose Insider